Pre-clinical study of panobinostat in xenograft and genetically engineered murine diffuse intrinsic pontine glioma models

Tammy Hennika, Guo Hu, Nagore G. Olaciregui, Kelly L. Barton, Anahid Ehteda, Arjanna Chitranjan, Cecilia Chang, Andrew J. Gifford, Maria Tsoli, David S. Ziegler, Angel M. Carcaboso, Oren J. Becher

Research output: Contribution to journalArticlepeer-review

122 Scopus citations


Background: Diffuse intrinsic pontine glioma (DIPG), or high-grade brainstem glioma (BSG), is one of the major causes of brain tumor-related deaths in children. Its prognosis has remained poor despite numerous efforts to improve survival. Panobinostat, a histone deacetylase inhibitor, is a targeted agent that has recently shown pre-clinical efficacy and entered a phase I clinical trial for the treatment of children with recurrent or progressive DIPG. Methods: A collaborative pre-clinical study was conducted using both a genetic BSG mouse model driven by PDGF-B signaling, p53 loss, and ectopic H3.3-K27M or H3.3-WT expression and an H3.3-K27M orthotopic DIPG xenograft model to confirm and extend previously published findings regarding the efficacy of panobinostat in vitro and in vivo. Results: In vitro, panobinostat potently inhibited cell proliferation, viability, and clonogenicity and induced apoptosis of human and murine DIPG cells. In vivo analyses of tissue after short-term systemic administration of panobinostat to genetically engineered tumor-bearing mice indicated that the drug reached brainstem tumor tissue to a greater extent than normal brain tissue, reduced proliferation of tumor cells and increased levels of H3 acetylation, demonstrating target inhibition. Extended consecutive daily treatment of both genetic and orthotopic xenograft models with 10 or 20 mg/kg panobinostat consistently led to significant toxicity. Reduced, well-tolerated doses of panobinostat, however, did not prolong overall survival compared to vehicle-treated mice. Conclusion: Our collaborative pre-clinical study confirms that panobinostat is an effective targeted agent against DIPG human and murine tumor cells in vitro and in short-term in vivo efficacy studies in mice but does not significantly impact survival of mice bearing H3.3-K27M-mutant tumors. We suggest this may be due to toxicity associated with systemic administration of panobinostat that necessitated dose de-escalation.

Original languageEnglish (US)
Article numbere0169485
JournalPloS one
Issue number1
StatePublished - Jan 2017

ASJC Scopus subject areas

  • General


Dive into the research topics of 'Pre-clinical study of panobinostat in xenograft and genetically engineered murine diffuse intrinsic pontine glioma models'. Together they form a unique fingerprint.

Cite this